Breakthrough Antiviral Candidate Targets Deadly Mosquito‑Borne Brain Virus

Antiviral candidate fights VEEV

Researchers at the University of Alabama in Huntsville have engineered a new class of antiviral candidate that demonstrates robust activity against Venezuelan equine encephalitis virus (VEEV), the most hazardous neurotropic alphavirus known to infect humans. In vitro assays revealed the compound slashed viral replication by ↑ 85% while animal models showed mortality reductions of ↓ 70%. These findings, published in the European Journal of Medicinal Chemistry, could reshape therapeutic strategies for mosquito‑borne encephalitides.

“Our work opens a pathway to clinically viable treatments for viruses that have long eluded effective therapy,” said lead scientist Dr. Maya Patel.

The team’s approach leverages structure‑based drug design to enhance viral polymerase inhibition, a method echoed in recent Reuters coverage of emerging antiviral platforms. Further pre‑clinical trials are slated for early next year, with potential collaboration with biotech firms hinted at in a Bloomberg report.